Company news
Aptorum Group Limited news in 2023
Aptorum Group Limited's news releases, calls and decks from 2023, newest first.
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
December 21, 2023
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders
December 20, 2023
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023
November 15, 2023
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
August 9, 2023
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma
June 21, 2023
Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris
June 8, 2023
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group
March 26, 2023
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus
March 2, 2023
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma
March 2, 2023
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China
March 1, 2023
Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023
February 5, 2023
Aptorum Group Announces 1-for-10 Reverse Stock Split
January 19, 2023
Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms
January 3, 2023